Proof of concept and development of a PSMA-targeting NO-releasing PDE5 inhibitor to explore eradication for metastatic prostate cancer

• Unité de recherche: INNOSUISSE
• Numéro de projet: 132.906 IP-LS
• Titre du projet anglais: Proof of concept and development of a PSMA-targeting NO-releasing PDE5 inhibitor to explore eradication for metastatic prostate cancer

Mots-clé (Anglais)

Life sciences, Pharmaceuticals

Résumé des résultats (Abstract) (Anglais)

Topadur continues the lead optimization program to identify an innovative and unique PSMA-targeting NO-releasing PDE5 inhibitor to boost radioligand therapy in advanced prostate cancer and to generate pivotal data to support partnering development with a big pharma.